Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Shares Climb 0.2% – Still a Buy?

Shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) rose 0.2% during mid-day trading on Friday. The stock traded as high as $10.71 and last traded at $10.67. 22,244 shares were traded during trading, a decline of 58% from the average daily volume of 53,227 shares. The stock had previously closed at $10.65.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Oaktree Acquisition Corp. III Life Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Hold rating. According to MarketBeat, the stock has an average rating of “Hold”.

Oaktree Acquisition Corp. III Life Sciences Stock Up 0.2%

The stock’s fifty day simple moving average is $10.77 and its 200-day simple moving average is $10.72.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.07 EPS for the quarter.

Institutional Investors Weigh In On Oaktree Acquisition Corp. III Life Sciences

A hedge fund recently raised its stake in Oaktree Acquisition Corp. III Life Sciences stock. Rangeley Capital LLC raised its stake in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) by 52.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,188 shares of the company’s stock after buying an additional 21,156 shares during the period. Rangeley Capital LLC owned approximately 0.25% of Oaktree Acquisition Corp. III Life Sciences worth $647,000 as of its most recent SEC filing.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with a company in the life sciences sector.

The company does not operate as a traditional commercial business and does not manufacture or sell products or provide healthcare services. Instead, its activities are focused on evaluating potential merger, acquisition, or other business combination opportunities involving businesses such as biotechnology, pharmaceuticals, medical devices, diagnostics, and related healthcare industries.

Oaktree Acquisition Corp.